JP2018501241A - 改良された細胞療法 - Google Patents

改良された細胞療法 Download PDF

Info

Publication number
JP2018501241A
JP2018501241A JP2017532859A JP2017532859A JP2018501241A JP 2018501241 A JP2018501241 A JP 2018501241A JP 2017532859 A JP2017532859 A JP 2017532859A JP 2017532859 A JP2017532859 A JP 2017532859A JP 2018501241 A JP2018501241 A JP 2018501241A
Authority
JP
Japan
Prior art keywords
subject
cell
cells
derived
msc
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2017532859A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018501241A5 (enExample
Inventor
グラハム・ヴェシー
エリザベス・エヴァンス
Original Assignee
セル・アイディアズ・ピーティーワイ・リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2014905156A external-priority patent/AU2014905156A0/en
Application filed by セル・アイディアズ・ピーティーワイ・リミテッド filed Critical セル・アイディアズ・ピーティーワイ・リミテッド
Publication of JP2018501241A publication Critical patent/JP2018501241A/ja
Publication of JP2018501241A5 publication Critical patent/JP2018501241A5/ja
Priority to JP2022035174A priority Critical patent/JP2022069524A/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/48—Reproductive organs
    • A61K35/54—Ovaries; Ova; Ovules; Embryos; Foetal cells; Germ cells
    • A61K35/545—Embryonic stem cells; Pluripotent stem cells; Induced pluripotent stem cells; Uncharacterised stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • C12N5/0663—Bone marrow mesenchymal stem cells (BM-MSC)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • C12N5/0667—Adipose-derived stem cells [ADSC]; Adipose stromal stem cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Developmental Biology & Embryology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Rheumatology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Reproductive Health (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Gynecology & Obstetrics (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2017532859A 2014-12-19 2015-12-18 改良された細胞療法 Pending JP2018501241A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2022035174A JP2022069524A (ja) 2014-12-19 2022-03-08 改良された細胞療法

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
AU2014905156A AU2014905156A0 (en) 2014-12-19 Improved cell therapies
AU2014905157 2014-12-19
AU2014905157A AU2014905157A0 (en) 2014-12-19 Improved cell-based therapies
AU2014905156 2014-12-19
AU2015901929A AU2015901929A0 (en) 2015-05-26 Improved cell therapies
AU2015901929 2015-05-26
PCT/AU2015/000755 WO2016094932A1 (en) 2014-12-19 2015-12-18 Improved cell therapies

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022035174A Division JP2022069524A (ja) 2014-12-19 2022-03-08 改良された細胞療法

Publications (2)

Publication Number Publication Date
JP2018501241A true JP2018501241A (ja) 2018-01-18
JP2018501241A5 JP2018501241A5 (enExample) 2019-02-07

Family

ID=56125431

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2017532859A Pending JP2018501241A (ja) 2014-12-19 2015-12-18 改良された細胞療法
JP2022035174A Pending JP2022069524A (ja) 2014-12-19 2022-03-08 改良された細胞療法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2022035174A Pending JP2022069524A (ja) 2014-12-19 2022-03-08 改良された細胞療法

Country Status (5)

Country Link
US (1) US20180221411A1 (enExample)
EP (1) EP3233097A4 (enExample)
JP (2) JP2018501241A (enExample)
AU (1) AU2015367275B2 (enExample)
WO (1) WO2016094932A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7773294B2 (ja) 2017-06-09 2025-11-19 ロート製薬株式会社 拡張型心筋症治療剤

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112020004856A2 (pt) * 2017-09-15 2020-09-15 Cynata Therapeutics Limited método para tratar doença alérgica das vias aéreas (aad)/asma
US10702547B2 (en) * 2018-05-16 2020-07-07 Aq Skin Solutions Inc. Compositions for treatment of arthritis
CA3103043A1 (en) * 2018-06-15 2019-12-19 Luis Marinas Pardo Pharmaceutical composition for dermatology and uses thereof
CA3225910A1 (en) * 2021-07-08 2023-01-12 Boehringer Ingelheim Veterinary Medicine Belgium Mesenchymal stem cells for use in the treatment of osteoarthritis in animals

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012106367A2 (en) * 2011-01-31 2012-08-09 Royal Daniel F Pluripotent stem cells and method of stimulating and extracting non-embryonic pluripotent stem cells from mammal blood and using reconstituted pluripotent stem cells to treat diseases including chronic obstructive pulmonary disease

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2013205141A1 (en) * 2008-08-22 2013-05-16 Regeneus Ltd. Therapeutic methods using adipose tissue-derived cell suspensions comprising adipocytes
AU2010347212B2 (en) 2010-09-14 2016-07-14 Cell Ideas Pty Ltd Cell free preparation and uses thereof
SG10201606745XA (en) * 2011-09-23 2016-10-28 Cell Ideas Pty Ltd Therapeutics using adipose cells and cell secretions
US9782440B2 (en) * 2012-02-16 2017-10-10 The Cleveland Clinic Foundation Methods for treating genitourinary disorders

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012106367A2 (en) * 2011-01-31 2012-08-09 Royal Daniel F Pluripotent stem cells and method of stimulating and extracting non-embryonic pluripotent stem cells from mammal blood and using reconstituted pluripotent stem cells to treat diseases including chronic obstructive pulmonary disease

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
EI-DENSHARY ESM, ET AL., J CLIN EXP PHARMACOL, JPN6019051133, 2012, pages 1 - 10, ISSN: 0004633590 *
EVE DJ, ET AL., CELL TRANSPLANTATION, vol. 20, JPN6019051135, 2011, pages 554, ISSN: 0004183598 *
JIN,H.K. ET AL., J CLIN INVEST, vol. 109, JPN6020051294, 2002, pages 1183 - 91, ISSN: 0004633591 *
LEE RH, ET AL., PROC NATL ACAD SCI U S A, vol. 111, JPN6019051136, November 2014 (2014-11-01), pages 16766 - 71, ISSN: 0004183599 *
STERN, M. ET AL., TRANSPLANTATION, vol. 82, JPN6020051292, 2006, pages 218 - 26, ISSN: 0004633592 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7773294B2 (ja) 2017-06-09 2025-11-19 ロート製薬株式会社 拡張型心筋症治療剤

Also Published As

Publication number Publication date
AU2015367275A1 (en) 2017-06-29
AU2015367275B2 (en) 2021-11-18
WO2016094932A1 (en) 2016-06-23
EP3233097A1 (en) 2017-10-25
EP3233097A4 (en) 2018-08-08
US20180221411A1 (en) 2018-08-09
JP2022069524A (ja) 2022-05-11

Similar Documents

Publication Publication Date Title
JP7022863B2 (ja) 脂肪細胞および細胞分泌物を使用する治療
Schnabel et al. Therapeutic use of stem cells in horses: which type, how, and when?
Prządka et al. The role of mesenchymal stem cells (MSCs) in veterinary medicine and their use in musculoskeletal disorders
JP2022069524A (ja) 改良された細胞療法
Bertoni et al. Intra‐articular injection of 2 different dosages of autologous and allogeneic bone marrow‐and umbilical cord‐derived mesenchymal stem cells triggers a variable inflammatory response of the fetlock joint on 12 sound experimental horses
Leal Reis et al. Allogenic synovia-derived mesenchymal stem cells for treatment of equine tendinopathies and desmopathies—Proof of concept
Nicpoń et al. The advantages of autologus adipose derived mesenchymal stem cells (AdMSCs) over the non-steroidal anti-inflammatory drugs (NSAIDs) application for degenerative elbow joint disease treatment in dogs-twelve cases.
JP2023002772A (ja) 脂肪細胞および細胞分泌物を使用する治療
AU2020257078B2 (en) Stem cells and secretions for treatment of inflammatory conditions
Alabdallah The Use of Stem Cells in the Treatment of Animal Diseases and Injuries
HK40015513A (en) Therapeutics using adipose cells and cell secretions
AU2013203072B2 (en) Therapeutic methods and compositions comprising cells and secretions
Brehm Evolution and actual state of veterinary regenerative medicine.
AU2013203073A1 (en) Stem cell secretions for topical treatment of skin conditions

Legal Events

Date Code Title Description
A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20180604

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20181217

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20181217

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200106

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20200406

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200703

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210112

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20210409

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210712

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20210713

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20211108